Vistagen Therapeutics (VTGN) EBIT (2011 - 2026)
Vistagen Therapeutics (VTGN) posted EBIT of -$16.7 million for Q1 2026, up 14.47% sequentially from -$19.5 million in Q4 2025, and down 15.33% YoY from -$19.7 million in Q1 2025.
Vistagen Therapeutics (VTGN) EBIT (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported EBIT for 15 years, with the latest figure at -$16.7 million in Q1 2026.
- Quarterly EBIT fell 15.33% year-over-year to -$16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$72.1 million (down 28.85% YoY) and the FY2026 annual result came in at -$72.1 million, down 28.86% from the prior year.
- EBIT advanced to -$16.7 million in Q1 2026 per VTGN's latest filing, from -$19.5 million in the prior quarter.
- Over five years, EBIT peaked at -$6.8 million in Q3 2023 and troughed at -$20.1 million in Q3 2025.
- A 5-year average of -$13.9 million and a median of -$14.5 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT tumbled 168.42% in 2022, then soared 64.61% in 2023.
- Over 5 years, EBIT stood at -$9.8 million in 2022, then rose by 19.28% to -$7.9 million in 2023, then slumped by 91.78% to -$15.1 million in 2024, then fell by 29.27% to -$19.5 million in 2025, then grew by 14.47% to -$16.7 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$16.7 million, -$19.5 million, and -$20.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -13.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.72 Mn |
| Dec 31, 2025 | -19.55 Mn |
| Sep 30, 2025 | -20.05 Mn |
| Jun 30, 2025 | -15.80 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -15.12 Mn |
| Sep 30, 2024 | -14.23 Mn |
| Jun 30, 2024 | -12.13 Mn |
| Mar 31, 2024 | -11.36 Mn |
| Dec 31, 2023 | -7.88 Mn |
| Sep 30, 2023 | -6.78 Mn |
| Jun 30, 2023 | -7.00 Mn |
| Mar 31, 2023 | -12.24 Mn |
| Dec 31, 2022 | -9.77 Mn |
| Sep 30, 2022 | -17.49 Mn |
| Jun 30, 2022 | -19.77 Mn |
| Mar 31, 2022 | -16.69 Mn |
| Dec 31, 2021 | -10.54 Mn |
| Sep 30, 2021 | -12.80 Mn |
| Jun 30, 2021 | -7.75 Mn |